Pharma News

In recent years, the biotech industry has been characterized by long periods of investment and development, with profitability often being elusive for many companies.

In a remarkable development, four cutting-edge Cellular and Gene Therapy (CGT) treatments have received approval, ushering in a new era of medical advancements.

This article explores the implications and controversies surrounding Kyowa Kirin's revolutionary gene therapy, which has become the most expensive drug ever launched in the country.

In the realm of oncology, advancements in targeted therapies have revolutionized the treatment landscape, offering hope and improved outcomes for patients battling various forms of cancer.

33rd Asia-Pacific Association for the Study of the Liver annual meeting, groundbreaking research findings regarding the effectiveness of magnesium isoglycyrrhizinate (MgIG) in treating liver injury caused by novel antineoplastic drugs were unveiled.

The orthopedic sector witnessed a significant development as a major player in the industry recently concluded a multi-billion dollar business sale.

In a groundbreaking development, CMS Pharmaceutical announced its exclusive partnership with Incyte on April 1st, signaling a significant breakthrough in the treatment of vitiligo.

In the highly competitive field of obesity treatment, a fierce competition is underway between Semaglutide and Tirzepatide.

In a groundbreaking move, Gilead Sciences has announced its exclusive licensing agreement with Xilio Therapeutics to jointly develop and commercialize XTX301, a promising tumor-activating protein known as Interleukin-12 (IL-12).

The year 2023 proved to be a defining period for China's innovation pharmaceutical industry, marked by remarkable achievements and valuable insights.

Incyte and CMS Pharmaceutical Holdings have entered into a strategic collaboration and licensing agreement for the development and commercialization of an oral JAK1 inhibitor in China and Southeast Asia.

Artificial intraocular lenses (IOLs) have emerged as a groundbreaking solution for several vision-related conditions, including cataracts, glaucoma, and refractive errors.

This article explores Pfizer's journey in the ADC landscape and highlights its key contributions to this innovative therapeutic approach.

In the rapidly evolving pharmaceutical industry, mergers and acquisitions (M&A) play a crucial role in shaping the competitive landscape.

In recent developments, WuXi AppTec, a leading Chinese pharmaceutical and biotechnology company, finds itself embroiled in controversy once more.

The field of AI pharmaceuticals has reached a significant milestone with the emergence of the first profitable company.

Novo Nordisk, one of Europe's leading pharmaceutical companies, is making significant strides in the field of cardiovascular therapeutics.

In a significant development for the field of dermatology, Hengrui Pharmaceuticals has received implicit approval for clinical trials of their groundbreaking class 1 drug, SHR-1139 injection, targeting psoriasis, a chronic inflammatory skin disease.

The field of Antibody-Drug Conjugates (ADCs) is experiencing an unprecedented surge in growth, positioning itself as a high-growth market with immense potential.

In a significant development for the pharmaceutical industry, a comprehensive volume-based procurement list has been announced, incorporating a staggering 1007 medicines.